在III期COMMODORE 2和1研究中，接受crovalimab和已获批的C5抑制剂治疗的阵发性夜间血红蛋白尿患者的患者报告结局。 - Suppr

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

作者信息

Panse Jens, Han Bing, Cermak Jaroslav, Gonzalez Fernandez Fernando Ataulfo, Gotoh Akihiko, Kulasekararaj Austin G, Kyselova Olena, Sahin Fahri, Scheinberg Phillip, Schrezenmeier Hubert, Straetmans Nicole, Ueda Yasutaka, Chang Alice C, Gentile Brittany, Stefani Jennifer, Uguen Marianne, Röth Alexander

机构信息

Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.

Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.

出版信息

Ann Hematol. 2025 Jun 14. doi: 10.1007/s00277-025-06449-0.

DOI:10.1007/s00277-025-06449-0

PMID:40515823

Abstract

摘要

相似文献

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

Ann Hematol. 2025 Jun 14. doi: 10.1007/s00277-025-06449-0.

Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria.

Health Sci Rep. 2025 Jul 13;8(7):e70986. doi: 10.1002/hsr2.70986. eCollection 2025 Jul.

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25.

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice.

Blood. 2025 Jul 24;146(4):411-421. doi: 10.1182/blood.2024027574.

Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.

Clin Adv Hematol Oncol. 2025 Jun;23 Suppl 8(4):1-19.

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Ann Hematol. 2025 Jan;104(1):81-94. doi: 10.1007/s00277-025-06193-5. Epub 2025 Jan 22.

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

Am J Hematol. 2024 Sep;99(9):1768-1777. doi: 10.1002/ajh.27412. Epub 2024 Jun 17.

Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.

Immunotherapy. 2024;16(20-22):1185-1196. doi: 10.1080/1750743X.2024.2433410. Epub 2024 Dec 2.

Two Cases of Crovalimab-Induced Platelet Recovery in Bone Marrow Failure-Associated Paroxysmal Nocturnal Hemoglobinuria (PNH).

Cureus. 2025 May 19;17(5):e84380. doi: 10.7759/cureus.84380. eCollection 2025 May.

Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.

Br J Clin Pharmacol. 2025 May;91(5):1479-1490. doi: 10.1111/bcp.16394. Epub 2025 Jan 21.

本文引用的文献

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Blood Adv. 2025 Apr 22;9(8):1816-1826. doi: 10.1182/bloodadvances.2024014652.

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Blood. 2025 Feb 20;145(8):811-822. doi: 10.1182/blood.2024026299.

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25.

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

Am J Hematol. 2024 Sep;99(9):1768-1777. doi: 10.1002/ajh.27412. Epub 2024 Jun 17.

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Blood. 2024 Mar 21;143(12):1157-1166. doi: 10.1182/blood.2023021762.

Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.

J Patient Rep Outcomes. 2023 Jul 5;7(1):63. doi: 10.1186/s41687-023-00609-4.

Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials.

JNCI Cancer Spectr. 2023 Mar 1;7(2). doi: 10.1093/jncics/pkad002.

The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.

Eur J Haematol. 2022 Oct;109(4):351-363. doi: 10.1111/ejh.13816. Epub 2022 Jul 7.

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.

Br J Haematol. 2022 Aug;198(3):e46-e50. doi: 10.1111/bjh.18274. Epub 2022 May 24.

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.

Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

作者信息

机构信息

Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.

Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.

出版信息

Ann Hematol. 2025 Jun 14. doi: 10.1007/s00277-025-06449-0.

DOI:10.1007/s00277-025-06449-0

PMID:40515823

Abstract

摘要

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

作者信息

机构信息

出版信息

相似文献

本文引用的文献